Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience

Table 1

Clinicopathological characteristics at diagnosis and details of final breast and axillary surgery. Gender is not displayed as all patients identified were female. The number of patients having axillary intervention amounts to greater than 100%, as 2 patients had sentinel lymph node biopsy as well as ANC. Axillary lymph node dissection.

Characteristic	Frequency (n, (%))
Median age (yrs) (IQR)	50 (44.4–60.2)
Grouped ages n (%)
<35 yrs	5 (6.4)
35–50 yrs	33 (42.3)
51–65 yrs	29 (37.2)
>65 yrs	11 (14.1)
Median BMI (kg/m^2) (IQR)	27 (23.2–29.4)
Postmenopausal n (%)	38 (49)
ECOG Performance score n (%)
0	66 (85)
1	12 (15)
Tumour laterality
Left	41 (51)
Right	39 (49)
Median tumour size (mm) (IQR)	30 (23.0–47.5)
T stage (mm)
T1; 0–20 mm	11 (13.8)
T2; 20–50 mm	54 (67.5)
T3; >50 mm	15 (18.8)
Nodal status n (%):
Positive	52 (65.0)
Negative	28 (35.0)
Histological subtype n (%):
Ductal	74 (92.5)
Lobular	2 (2.5)
Other	4 (5.0)
Inflammatory breast cancer	4 (5.0)
Histological grade (core biopsy) n (%)
1	2 (2.5)
2	31 (38.8)
3	47 (58.8)
Receptor status
ER+, PgR+	19 (23.8)
ER+, PgR−	14 (17.5)
ER+, PgR unknown	23 (28.8)
ER−, PgR−	23 (28.8)
ER−, PgR unknown	1 (1.3)
Breast surgery
Mastectomy	41 (51.3)
Breast conservation	39 (48.7)
Axillary surgery
Sentinel lymph node biopsy	46 (57.5)
Axillary lymph node dissection	36 (45.0)